| Literature DB >> 18800759 |
Ming-Qiang Zhang1, Sabine Gaisser, Mohammad Nur-E-Alam, Lesley S Sheehan, William A Vousden, Nikolaos Gaitatzis, Gerrard Peck, Nigel J Coates, Steven J Moss, Markus Radzom, Teresa A Foster, Rose M Sheridan, Matthew A Gregory, S Mark Roe, Chrisostomos Prodromou, Laurence Pearl, Susan M Boyd, Barrie Wilkinson, Christine J Martin.
Abstract
A biosynthetic medicinal chemistry approach was applied to the optimization of the natural product Hsp90 inhibitor macbecin. By genetic engineering, mutants have been created to produce novel macbecin analogues including a nonquinone compound (5) that has significantly improved binding affinity to Hsp90 (Kd 3 nM vs 240 nM for macbecin) and reduced toxicity (MTD > or = 250 mg/kg). Structural flexibility may contribute to the preorganization of 5 to exist in solution in the Hsp90-bound conformation.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18800759 DOI： 10.1021/jm8006068
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446